REG - AstraZeneca PLC - AstraZeneca agrees to buy US FDA Priority Review

AstraZenecaAnnouncement

22/08/2019 07:05

RNS Number : 8484J
AstraZeneca PLC
22 August 2019
 


22 August 2019 07:00 BST
 
AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi
 
AstraZeneca today announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi).
 
A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead to an expedited approval.
 
The transaction is subject to clearance under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.
 
For the purposes of the UK Listing Authority's Listing Rule LR 10.4.1 R (Notification of class 2 transactions), the total book value of gross assets attributable to the PRV is equivalent to the full consideration of $95m. No operating profit or loss was attributable to the PRV in prior accounting periods at Sobi.
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.




 
 
Media Relations


 


 




Gonzalo Viña


 


+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharmaceuticals


+44 203 749 5906




Jennifer Hursit


Other


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677




 


 


 




Investor Relations


 


 




Thomas Kudsk Larsen


 


+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharmaceuticals (CV, metabolism)


+44 203 749 5711




Nick Stone


BioPharmaceuticals (respiratory, renal)


+44 203 749 5716




Josie Afolabi


Other medicines


+44 203 749 5631




Craig Marks


Finance, fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access, retail investors


+44 203 749 5824




US toll-free


 


+1 866 381 72 77






Adrian Kemp

Company Secretary

AstraZeneca PLC
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRSEEEFFFUSESA